Filing Flows › Comparisons › SKVI vs LYEL
Skinvisible vs Lyell Immunopharma: SKVI and LYEL compared
Skinvisible is the larger company: $5K of revenue in its latest quarter (Q2 2026) against $3K for Lyell Immunopharma (Q3 2026). Skinvisible is growing faster (0% against -80% a year earlier).
Where the money goes: SKVI and LYEL
Skinvisible (SKVI) · Q2 2026
Skinvisible, Q2 2026: revenue $5K (0% year over year), net loss $256K, operating cash flow $2K. The chart follows the revenue to costs, profit and cash.
Lyell Immunopharma (LYEL) · Q3 2026
Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
| Skinvisible (SKVI) | Lyell Immunopharma (LYEL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $5K | $3K |
| Revenue growth, Y/Y | 0% | -80% |
| Operating margin | n/m | n/m |
| Net earnings | −$256K | −$45.5M |
| Operating cash flow | $2K | −$34.6M |
Questions
Which is bigger, Skinvisible or Lyell Immunopharma?
Skinvisible is the larger company: $5K of revenue in its latest quarter (Q2 2026) against $3K for Lyell Immunopharma (Q3 2026).
Is Skinvisible or Lyell Immunopharma growing faster?
Skinvisible is growing faster (0% against -80% a year earlier).
More: Skinvisible earnings · how Skinvisible makes money · Lyell Immunopharma earnings · how Lyell Immunopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.